Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290-Reference-Cited by-同舟云学术

Human Relaxin Receptor Is Fully Functional in Humanized Mice and Is Activated by Small Molecule Agonist ML290

Published:2017-05-08 Issue:6 Volume:1 Page:712-725
ISSN:2472-1972
Container-title:Journal of the Endocrine Society
language:en
Short-container-title:

Author:

Kaftanovskaya Elena M.,Soula Mariluz,Myhr Courtney,Ho Brian A.,Moore Stefanie N.,Yoo Changwon,Cervantes Briana,How Javier,Marugan Juan,Agoulnik Irina U.,Agoulnik Alexander I.

Publisher

The Endocrine Society

Subject

Endocrinology, Diabetes and Metabolism

Link

http://academic.oup.com/jes/article-pdf/1/6/712/17666647/js.2017-00112.pdf

Reference21 articles.

1. Relaxin’s physiological roles and other diverse actions;Endocr Rev,2004

2. International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides;Pharmacol Rev,2015

3. Anti-fibrotic actions of relaxin;Br J Pharmacol,2017

4. Effects of relaxin on arterial dilation, remodeling, and mechanical properties;Curr Hypertens Rep,2011

5. Mice without a functional relaxin gene are unable to deliver milk to their pups;Endocrinology,1999

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic potential of relaxin or relaxin mimetics in managing cardiovascular complications of diabetes;Biochemical Pharmacology;2024-11

2. Engineering a long acting, non-biased relaxin agonist using Protein-in-Protein technology;Biochemical Pharmacology;2024-09

3. Identification of Novel Series of Potent and Selective Relaxin Family Peptide Receptor 1 (RXFP1) Agonists;Journal of Medicinal Chemistry;2024-03-19

4. R2R01: A long‐acting single‐chain peptide agonist of RXFP1 for renal and cardiovascular diseases;British Journal of Pharmacology;2024-03-07

5. Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure;British Journal of Pharmacology;2023-03-08